首页|活力骨康方治疗原发性骨质疏松症的临床疗效及对骨转换指标的影响

活力骨康方治疗原发性骨质疏松症的临床疗效及对骨转换指标的影响

扫码查看
目的 观察活力骨康方对原发性骨质疏松症的治疗效果及对骨转换指标的影响.方法 选择 2021 年 1月至2021 年12 月收治的40 例原发性骨质疏松症患者为研究对象,按照随机数字表法分为2 组,对照组20 例予西医常规治疗,治疗组20 例在对照组基础上联合活力骨康方治疗.2 组均治疗 6 个月,并在治疗结束后随访 6 个月,比较 2 组治疗前及随访1、6 个月疼痛视觉模拟评分法(VAS)评分及Oswestry功能障碍指数问卷表(ODI)评分变化情况,比较2 组治疗前及随访6 个月骨密度T值变化情况,比较2 组治疗前及随访1、6 个月骨转换标志物血清总Ⅰ型前胶原氨基端肽(t-P1NP)及β胶联降解产物(β-CTX)水平变化情况.结果 与本组治疗前比较,2 组随访1、6 个月疼痛VAS评分及ODI评分均降低(P<0.05),且治疗组随访1、6 个月疼痛VAS评分及ODI评分均低于对照组随访同期(P<0.05).与本组治疗前比较,2 组随访6 个月第1~4 腰椎、右侧髋骨及右侧股骨颈骨密度T值均升高(P<0.05),且治疗组随访 6 个月第1~4 腰椎、右侧髋骨及右侧股骨颈骨密度T值均高于对照组随访同期(P<0.05).与本组治疗前比较,2 组随访1、6 个月骨转换指标血清t-P1NP水平均升高(P<0.05),β-CTX水平均降低(P<0.05),且治疗组随访 1、6 个月血清t-P1NP水平高于对照组随访同期(P<0.05),β-CTX水平低于对照组随访同期(P<0.05).结论 活力骨康方治疗原发性骨质疏松症疗效确切,可有效缓解骨痛症状,改善肢体功能,提高骨密度,提高t-P1NP水平,促进骨形成,降低β-CTX水平,抑制骨吸收.
Clinical study on Huoli Gukang Formula on primary osteoporosis and its influence on bone turnover markers
Objective To explore the clinical research of Huoli Gukang Formula on primary osteoporosis and its influ-ence on bone turnover markers.Methods Forty patients with primary osteoporosis who visited our hospital from January 2021 to December 2021 were selected as the research subjects.They were randomly assigned into the control group(routine Western medicine[RWM],n =20)or the treatment group(Huoli Gukang Formula +RWM,n =20).A 9-month treatment and 6-month follow-up were performed.Before treatment and at 1 and 6 months of follow-up,the scores of pain visual analogue scale(VAS)and Oswestry Disability Index(ODI)questionnaires,the T value of bone mineral density(BMD),the serum levels of total procollagen type 1 N-terminal propeptide(t-P1NP)and beta-isomerized C-terminal telopeptide of type I collagen(β-CTX)in bone turnover markers were included as comparators between the two groups.Results At 1 and 6 months of fol-low-up,the VAS and ODI scores in the two groups were significantly lower than those before treatment(P<0.05),which in the treatment group decreased significantly compared to the control group(P<0.05).The T value of BMD of lumbar vertebrae L1-L4,right hip and right femoral neck at 6 months of follow-up in the both groups was significantly higher than that before treatment(P<0.05),and the treatment group was superior to the control group for the T value of BMD(P<0.05).The levels of t-PINP at 1 and 6 months of follow-up in the both groups were significantly higher than those before treatment,and the improve-ment was more pronounced in treatment group than in the control group(P<0.05).The level of β-CTX at1 and6 months of fol-low-up in the both groups was significantly decreased than before treatment(P<0.05),which was significantly lower in the treatment group relative to the control group(P<0.05).Conclu-sion The application of Huoli Gukang Formula has exact curative for primary osteoporosis,which can effectively relieve clinical symptoms,improve bone turnover,and increase bone density.It is capable increasing t-P1NP,promoting bone formation,re-ducing β-CTX,and inhibiting bone resorption.

OsteoporosisBone formationBone resorptionChinese medicine therapy

张根、杨澔侠、王正凯

展开 >

江苏省无锡市第九人民医院中医骨伤科,江苏 无锡 214062

骨质疏松症 骨形成 骨吸收 中药疗法

无锡市第九人民医院院级科研项目

JY20210717

2024

河北中医
河北省医学情报研究所,河北省中医药学会

河北中医

CSTPCD
影响因子:0.951
ISSN:1002-2619
年,卷(期):2024.46(4)
  • 25